TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is an appropriate candidate for niacin therapy (at risk for heart disease) and triglycerides \< 500 mg/dL~Exclusion Criteria:~* Patients with a history of any cardiovascular event directly linked to atherosclerosis with a low density lipoprotein-cholesterol (LDL-C) \>/= 130 mg/dL and/or not on a statin~* Patients with diabetes and LDL-C \>/= 130 mg/dL. Patients with \>/= 2 heart disease risk factors and LDL-C \>/= 160 mg/dL.~* Patients who have had a cardiovascular event (e.g., heart attack, stroke) within the previous 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females at least 18 years of age, but not older than 40~2. ACL injury requiring reconstruction~3. Have undergone unilateral ACL reconstruction surgery within six months of injury;~4. Willing and able to undertake a standardized rehabilitation protocol~5. ACL graft used is autograft~6. Willingness to participate in follow-up for 24 months from the time of initial treatment~7. Ability to understand and willingness to sign consent form~Exclusion Criteria:~1. Women who are pregnant or breast feeding or planning to become pregnant during the study~2. Previous allergic reaction to Hyaluronan~3. Systemic or local infection at the screen visit or at the time of the study injection~4. History of any autoimmune disease, such as, systemic lupus erythematosus, Addison's disease, Crohn's disease, or rheumatoid arthritis~5. Treatment with immunosuppression therapy within 6 months prior to screen (visit 1)~6. Acute or chronic infectious disease, including but not limited to human immunodeficiency virus (HIV);~7. Treatment and /or uncompleted follow-up treatment of any investigational therapy within 6 months before the procedure and /or intent to participate in any other investigational drug or cell therapy study during the 24 month follow-up period of this study;~8. Recipient of prior allogeneic stem cell/progenitor cell therapy~9. Undergoing a simultaneous procedure to the opposite knee~10. 20% or greater anti-human leukocyte antigen (HLA) antibody titer and/or has antibody specificities to donor HLA antigens;~11. Known sensitivities to bovine (cow), murine (mouse), chicken products and/or dimethylsulfoxide (DMSO). Previous allergic reaction to Hyaluronan;~12. History or current evidence of alcohol or drug abuse or is a recreational user of illicit drugs or prescription medications~13. History of prior surgery to the study knee joint~14. History of malignancy (excluding basal cell carcinoma that has been successfully excised)~15. Chondral lesions noted at time of surgical reconstruction greater than Grade 1a on any surfaces

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Hyaluronan Alone (Type: ACTIVE_COMPARATOR): Hyaluronan Alone
- MSB-CAR001 (Type: EXPERIMENTAL): Single Dose of MSB-CAR001 Combined With Hyaluronan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed marginal zone B-cell lymphomas~* Failure to achieve a clinical benefit (≥SD) with the initial treatment, or recurrent disease~* Performance status (ECOG) ≤2~* Age ≥ 20~* At least one or more bi-dimensionally measurable lesion(s) defined as; ≥2 cm by conventional CT or ≥ 1 cm by spiral CT or skin lesion (photographs should be taken) or measurable lesion by physical examination~* Adequate kidney functions defined as; Cr \< 2.0 mg% or Ccr \> 60 ml/min~* Adequate liver functions defined as; Transaminases \< 3 X upper normal values; Bilirubin \< 2 mg%~* Adequate bone marrow functions defined as; ANC \> 1500/㎕, platelet \> 75000/㎕~* Ann Arbor stage III or IV~* Ann Arbor stage I or II, which is not adequate for RT or surgical approach (e.g. multiple lung lesions, multiple colon involvement, remote abdominal LN with stomach involvement)~* Written informed consent approved by Institutional review board or Ethic committee~Exclusion Criteria:~* Any other malignancies within the past 5 years except skin basal cell ca or CIS of cervix~* Serious co-morbid diseases~* Pregnancy or breast feeding~* Previous history of drug allergy to one of the drugs in the study regimen~* During this study duration, patients who take other clinical trial medication, chemotherapy, hormonal therapy, or immunotherapy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OXP (Type: EXPERIMENTAL): Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2HR D1 Prednisolone 100mg/Day D1-D5 Every 3 weeks Maximum 6 cycles of treatment will be given for this study. Subjects will be treated for at least 1 cycle and to a maximum of 6 cycles unless there is documented disease progression, unacceptable adverse events or withdrawal of consent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ocular Hypertension Treatment Study (OHTS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Men and nonpregnant women between the ages of 40 and 80 with IOP greater than or equal to 24 mm Hg but less than or equal to 32 mm Hg in at least one eye and IOP greater than or equal to 21 but less than or equal to 32 mm Hg in the fellow eye, as well as normal visual fields and optic discs are eligible for the trial. Patients presenting with best-corrected visual acuity worse than 20/40 in either eye, previous intraocular surgery, a life-threatening or debilitating disease, secondary causes of elevated IOP, angle-closure glaucoma or anatomically narrow angles, other diseases that can cause visual field loss, background diabetic retinopathy, optic disc abnormalities that can produce visual field loss or obscure the interpretation of the optic disc, or unwillingness to undergo random assignment are excluded from the trial.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Observation (Type: NO_INTERVENTION): Close Observation.
- Treatment (Type: OTHER): Participants treated with commercially available topical ocular hypotensive eye drops.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* You are an outpatient diagnosed with stable schizophrenia.~* You are a male or female in the age of 18 to 65 years old.~* You are retrospectively judged by investigators, based on clinical interview and impression, to have been stable for at least 4 weeks.~* You must be able to take olanzapine orodispersible in a single daily dose.~* You are treated with conventional oral olanzapine tablet (as monotherapy) for at least 1 month.~Exclusion Criteria:~* You have used olanzapine in the past and are no longer using it because of a bad reaction.~* You have known Human immunodeficiency virus positive (HIV+) status.~* You have known uncorrected, narrow angle glaucoma.~* You have known Leukopenia, (abnormally low white blood cell count).~* You have a serious or uncontrolled illness (for example: liver disease, history of heart disease, or inadequately controlled diabetes.)~* You have Parkinson's disease.~* You are a female patient who is either pregnant or nursing~* You are taking medications that are not allowed in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First course of chemotherapy ( cisplatin or doxorubicin at a dose of at least 50mg per square meter)~* Written informed consent must be obtained before initiating the protocol procedures~Exclusion Criteria:~* ECOG 3~* Nausea and vomiting within the past 1 day~* Gastrointestinal obstruction~* Concurrent use of opioid~* Patients with brain metastases~* History of allergic or other adverse reaction to gabapentin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): Placebo:~* Five and four days before chemotherapy (day -5 and day -4): 1x daily~* Three and two days before chemotherapy (day -3 and day -2): 2x daily~* One day before to five days after chemotherapy ( day -1 to day 5): 3x daily
- Gabapentin (Type: EXPERIMENTAL): Gabapentin 300mg:~* Five and four days before chemotherapy (day -5 and day -4): 1x daily~* Three and two days before chemotherapy (day -3 and day -2): 2x daily~* One day before to five days after chemotherapy ( day -1 to day 5): 3x daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Nebivolol on Subclinical Left Ventricular dySfunction: A Comparative Study Against Metoprolol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 18 years or older, men and women, hospitalized and outpatients~* with a history of primary arterial hypertension~* with a daytime ambulatory blood pressure \>140 and/or \>90 mm Hg~* with left ventricular hypertrophy: LVMI \> 125 g/m2 for men, and \> 110 g/m2 for women, by Devereux formula, as recommended by the ESH-ESC guidelines (14)~* in sinus rhythm~* consented, by signing the Informed Consent~Exclusion Criteria:~* Severe arterial hypertension (systolic blood pressure \> 180 mm Hg and/or diastolic blood pressure \> 110 mm Hg)~* Any history of coronary heart disease (stable angina, acute coronary syndromes, myocardial infarction)~* Any history of cerebrovascular disease~* Renal impairment (creatinine \> 1.5 mg% for men, \> 1.4 mg% for women)~* Left ventricular global systolic dysfunction (EF \< 45%)~* More than mild valvar (mitral or aortic) regurgitation~* Hypertrophic cardiomyopathy~* Pericarditis~* Cor pulmonale~* Pregnancy or lactating women~* Any significant co-morbidities~* Contraindication to beta-blocker therapy~* Concomitant treatment with other beta-blockers~* Participation to another investigational study in the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nebivolol (Type: EXPERIMENTAL): None
- Metoprolol (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duration of Antibiotic Treatment for Early VAP (DATE) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Surgical patient~2. VAP, defined as clinical suspicion plus a bronchoalveolar lavage (BAL) culture showing ≥105 cfu/mL of at least one pathogen. The quantitative microbiology threshold will be lowered to ≥104 cfu/mL if the patient was being treated with antibiotics to which the pathogen is sensitive at the time of the BAL. Clinical suspicion of VAP is defined as at least one point for ≥ 2 variables in the Clinical Pulmonary Infection Score (CPIS, described below).~3. Ventilated ≤ 5 days at the time that the BAL was obtained.~4. Hospital LOS ≤ 5 days at the time that the BAL was obtained.~Exclusion Criteria:~1. Age \< 18 years.~2. Prior episode of VAP for the index admission (the patient may have had prior BALs sent for culture, but these cannot have met the above mentioned diagnostic criteria for VAP).~3. VAP caused by a MDR pathogen: Early VAP is rarely caused by a MDR pathogen; in a recent analysis of our surgical ICU, 94% of cases of early VAP were caused by a highly sensitive pathogen (MSSA 39%, H flu 35%, S. pneumo 16%, E. coli 9%) (Pieracci in press). Patients with early VAP caused by the following MDR pathogens will be excluded: Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-intermediate Staphylococcus aureus (VISA), pseudomonas aeruginosa, Vancomycin-resistant enterococcus (VRE), Acinetobacter baumannii, Stenotrophomonas maltophilia, and extended-spectrum beta lactamase producing gram negative bacilli.~4. Antibiotic therapy for ≥ 5 of the last 10 days preceding the BAL.~5. Septic shock, defined as evidence of tissue hypoperfusion after adequate volume expansion, due to infection, and requiring ≥ 1 vasopressor.~6. Current or recent (within 30 days) use of immunosuppressive medications.~7. Length of stay ≥ 48 hours in a transferring facility.~8. Inpatient hospitalization within 30 days of admission.~9. Pregnancy or lactation.~10. Legal arrest or incarceration.~11. Moribund state in which death is imminent.~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Default 4 days antibiotic therapy (Type: ACTIVE_COMPARATOR): Default 4 days antibiotic therapy
- Default 8 days antibiotic therapy (Type: NO_INTERVENTION): Default 8 days antibiotic therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of 2L NRL994 With NaP Preparation in Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject's written informed consent had to be obtained prior to inclusion.~2. Male or female ambulatory subjects with an age of 18 to 85 years planned to undergo a complete colonoscopy for colon cancer screening~3. Willing, able and competent to complete the entire procedure and to comply with study instructions~4. Females of childbearing potential had to employ an adequate method of contraception~Exclusion Criteria:~1. Ileus~2. Intestinal obstruction or perforation~3. Toxic megacolon~4. History of colonic resection~5. Requirement for permanent medication and associated stable serum concentrations (e.g. neuroleptic drugs)~6. Congestive heart failure (NYHA III + IV)~7. Acute life threatening cardiovascular disease~8. Untreated or uncontrolled arterial hypertension (max. \> 170 mmHg and min \> 100 mmHg)~9. Known moderate to severe renal insufficiency~10. Severe renal failure~11. Severe liver failure~12. Known glucose 6 phosphatase dehydrogenase deficiency~13. Known phenylketonuria~14. Known hypersensitivity to polyethylene glycols, NaP and/or Vitamin C~15. Concurrent participation in an investigational drug study or participation within 30 days of study entry~16. Females who were pregnant, nursing or planning a pregnancy. Females of child bearing potential not using reliable methods of contraception~17. Subject had a condition or was in a situation, which in the investigators opinion might have put the subject at significant risk, might confound the study results, or might interfere significantly.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 2L gut cleansing solution
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Probiotics BIFILACT® on Diarrhea in Patients Treated With Pelvic Radiation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* They had a pelvic cancer: gynecologic, rectal, or prostatic,they were to receive radiotherapy treatments for a minimum of 40 Gy at the pelvic level , with or without chemotherapy and they had Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1~Exclusion Criteria:~* they had previous radiotherapy treatments in the pelvic or abdominal region, medical history of gastro-intestinal inflammation, malabsorption syndrome or inflammatory bowel disease or coeliac disease, ileostomy, daily use of anti-diarrheal medication before radiotherapy, pregnancy or breastfeeding, neutropenia or probiotics intolerance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bifilact® probiotics standard dose (Type: ACTIVE_COMPARATOR): concentration of 1.3 billion of Lactobacillus acidophilus LAC-361 and Bifidobacterium longum BB-536. one pill twice a day. Each capsule contained maltodextrin and magnesium stearate as excipient
- Bifilact® probiotics high dose (Type: ACTIVE_COMPARATOR): containing 10 billion Lactobacillus acidophilus LAC-361 and Bifidobacterium longum BB-536. One pill three times a day. Each capsule contained maltodextrin and magnesium stearate as excipient
- placebo (Type: PLACEBO_COMPARATOR): Each capsule contained maltodextrin and magnesium stearate as excipient. One pill twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CO-OPerative Training for Stroke Rehabilitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* primary diagnosis of acute stroke~* admission to acute inpatient rehabilitation~* impairment in cognitive functions (Quick Executive Interview ≥ 3)~Exclusion Criteria:~* dementia diagnosis (as indicated in the medical record)~* severe aphasia as indicated by score ≥ 2 on the Boston Diagnostic Aphasia Examination (3rd Edition) Severity Rating Scale (BDAE-3)~* current major depressive disorder (unless treated and in partial remission), bipolar or any other psychotic disorder (Primary Care Evaluation of Mental Disorders)~* drug or alcohol abuse within 3 months (Mini-International Neuropsychiatric Interview)~* anticipated length of stay less than 5 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CO-OP (Type: EXPERIMENTAL): Cognitive Orientation to daily Occupational Performance (CO-OP) is a strategy training approach that trains individuals to identify problems in the performance of their daily activities, develop strategies to address these problems, and monitor their own performance in the course of their daily routines. Participants use a workbook to support their application of the strategy training.
- Attention Control (Type: PLACEBO_COMPARATOR): The attention control intervention controls for the non-specific effects of strategy training. The therapists administer the standardized and dose-matched protocol, using scripted open-ended questions to facilitate participants' reflections on their rehabilitation activities and experiences. Participants complete a daily journal, merely reviewing their rehabilitation activities.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete